Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
about
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutationsFirst-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancerNon-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesIs there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancerClinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challengesShould Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized TrialsMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularK-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValueEGFR mutations as a prognostic and predictive marker in non-small-cell lung cancerEGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidenceIrreversible EGFR-TKIs: dreaming perfectionSecond-Line Therapy for Advanced NSCLCUse of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic reviewOne mouse, one patient paradigm: New avatars of personalized cancer therapyA murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancerInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaPrognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study.Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysisIs There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials.Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancerGefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis.Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials.EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinomaMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularEconomic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized MedicineTargeting the EGFR signaling pathway in cancer therapy.EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.The BATTLE trial: personalizing therapy for lung cancer.Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLCImpact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.Distinct allelic expression patterns of imprinted IGF2 in adenocarcinoma and squamous cell carcinoma of the lung.
P2860
Q21132357-EAF4C526-83AB-4343-B7E5-0B7CEB335296Q21198843-F8016712-461F-4B9D-AFFE-098BF6ADB6F5Q26741814-C493341D-3BEA-493A-A2D7-457E4782AEA7Q26797297-BB0AFD6A-5052-4491-9BD0-A4ED3D88DED8Q26798882-013C8516-52BF-45CF-9F18-34AC14F82F05Q26801357-6088A0BD-37DC-4DC0-92F6-3E48DC706CD1Q26823978-B2D6F4DD-9229-461A-9CBE-AF1DC65415B1Q26825636-AB36BC05-93F7-4587-B8FE-673D206B6CBEQ26828860-A88E6164-2598-47C5-A908-82993D477B1BQ26829425-9667E991-7880-4715-9D90-80396CCEFF4BQ26852507-601EC805-C203-4D9F-8724-F9565AB70D49Q26853071-1A4439FA-3E51-4718-904A-1DC8F5A418C1Q26866186-8A0705B2-74BA-4635-BCAA-FB49DF2424E2Q27002398-DA1EA738-41DC-4FD1-A71A-8186AA79E460Q27022535-73CC9D8C-6FFF-4D8A-A116-85D9A1865181Q27023342-F9BC802E-9FBF-4616-AE75-C98DF269533FQ27851728-2E5240E0-C3C6-4916-8258-9408D14A6FA5Q27852543-22337ABA-5114-40F8-BD39-908F10577CA1Q28303718-7FF00F15-A9E8-4928-AB7B-7D0D6DBCD6A9Q30498101-C26AC0F4-9B0C-492D-8CDD-F43682879850Q30539397-27C5B12A-36F9-4E35-A4F2-D6210334FDE1Q33407582-453BF3D5-4855-47C7-ADA4-C1203C79A553Q33421419-0273D6B9-B209-45D5-98C4-63AF941FEBD7Q33423782-4F1BC3E5-6DEF-4BB9-A041-721F73AE4A29Q33441413-0D6DA724-0061-4C93-BB95-48E92EB0B894Q33648808-A518C0F7-62D0-4EF2-8348-16E637AF95F4Q33710152-9C5A95A6-05C8-42BA-BCA3-CA4DE2FE433FQ33781655-F39D4C26-E8D2-4A05-AED8-9CDA867C0B18Q33829668-92E46A4D-291D-47BC-BE16-8D8B9ABBA6CBQ33892582-E53BCA00-F792-480C-9041-084548BCBBA5Q34094224-2F48F73C-CBA1-4D23-A758-FD5F36CE19D2Q34108365-0AB98C38-3068-49C1-AAFE-4A7A5AEC24F9Q34159011-28F2AF4F-E14A-4329-9F6D-5B46D2274655Q34219452-0390A7A7-AB39-4F76-821A-8AEBE6205B26Q34246558-132FAC93-8328-4D32-9062-A9B92215810AQ34250003-A90DF889-6EBA-4E70-9138-9447F938A61CQ34275011-2B4DFB6D-AC7C-4518-B840-0F275B0F4846Q34311186-CB170AFA-A5B4-4B8E-84A7-51E96745B50AQ34339890-FF06393E-74C3-4275-BDF4-B69387C81728Q34427314-75300549-2839-4E80-9EA5-13200463E70D
P2860
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Molecular predictors of outcom ...... ized phase III INTEREST trial.
@ast
Molecular predictors of outcom ...... ized phase III INTEREST trial.
@en
Molecular predictors of outcom ...... ized phase III INTEREST trial.
@nl
type
label
Molecular predictors of outcom ...... ized phase III INTEREST trial.
@ast
Molecular predictors of outcom ...... ized phase III INTEREST trial.
@en
Molecular predictors of outcom ...... ized phase III INTEREST trial.
@nl
prefLabel
Molecular predictors of outcom ...... ized phase III INTEREST trial.
@ast
Molecular predictors of outcom ...... ized phase III INTEREST trial.
@en
Molecular predictors of outcom ...... ized phase III INTEREST trial.
@nl
P2093
P356
P1476
Molecular predictors of outcom ...... ized phase III INTEREST trial.
@en
P2093
Alison A Armour
Claire L Watkins
Edward S Kim
Frances A Shepherd
Georgina Speake
Helge Bischoff
Mark A Socinski
Mark V Sellers
Martin Reck
Mei-Lin Liao
P304
P356
10.1200/JCO.2009.24.3030
P407
P577
2009-12-28T00:00:00Z